Riluzole for motor neurone disease

BMJ

Volumn 323, Issue 7312, 2001, Pages 573-

  Barnett, David ^a   Ford, Martin ^b   Leperlier, Cyrille ^b  

^a Natl Inst for Clinical Excellence   (United Kingdom)

^b Aventis Pharma   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INFORMATION; HUMAN; LETTER; META ANALYSIS; MOTOR NEURON DISEASE; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; SURVIVAL RATE;

EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; MOTOR NEURON DISEASE; NEUROPROTECTIVE AGENTS; RILUZOLE;

EID: 0035828448     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.323.7312.573     Document Type: Letter

References (6)

1. Correspondence. Riluzole for motor neurone disease. BMJ 2001; 322: 1305–1306. (26 May.)
2. Sandercock J, Burls A, Hyde C, Fry-Smith A, Barton P, Bryan S, et al. Riluzole for motor neurone disease. BMJ 2001; 322: 1305. (26 May.)
3. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). In:Cochrane database of systematic reviews. Issue 3. Oxford: Oxford Software, 2000.
4. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.
5. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425–1431.
6. Rivière M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526–528.